These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 20630459

  • 1. Post-thienopyridine platelet response, cardiovascular outcomes, and personalized therapy: En attendant Godot.
    Tsimikas S, Leibundgut G.
    JACC Cardiovasc Interv; 2010 Jun; 3(6):657-9. PubMed ID: 20630459
    [No Abstract] [Full Text] [Related]

  • 2. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
    El Ghannudi S, Ohlmann P, Meyer N, Wiesel ML, Radulescu B, Chauvin M, Bareiss P, Gachet C, Morel O.
    JACC Cardiovasc Interv; 2010 Jun; 3(6):648-56. PubMed ID: 20630458
    [Abstract] [Full Text] [Related]

  • 3. Platelet function analysis: at the edge of meaning.
    Oestreich JH, Smyth SS, Campbell CL.
    Thromb Haemost; 2009 Feb; 101(2):217-9. PubMed ID: 19190799
    [No Abstract] [Full Text] [Related]

  • 4. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting.
    Cuisset T, Frere C, Poyet R, Quilici J, Gaborit B, Bali L, Brissy O, Lambert M, Morange PE, Alessi MC, Bonnet JL.
    Arch Cardiovasc Dis; 2010 Jan; 103(1):39-45. PubMed ID: 20142119
    [Abstract] [Full Text] [Related]

  • 5. Another view on prasugrel.
    Calatzis A.
    Thromb Haemost; 2009 Jan; 101(1):12-3. PubMed ID: 19132183
    [No Abstract] [Full Text] [Related]

  • 6. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
    Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma B.
    J Thromb Haemost; 2012 Apr; 10(4):529-42. PubMed ID: 22260716
    [Abstract] [Full Text] [Related]

  • 7. Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials.
    Faxon DP.
    Nat Rev Cardiol; 2010 Mar; 7(3):124-5. PubMed ID: 20179718
    [No Abstract] [Full Text] [Related]

  • 8. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
    Aleil B, Jacquemin L, De Poli F, Zaehringer M, Collet JP, Montalescot G, Cazenave JP, Dickele MC, Monassier JP, Gachet C.
    JACC Cardiovasc Interv; 2008 Dec; 1(6):631-8. PubMed ID: 19463377
    [Abstract] [Full Text] [Related]

  • 9. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis.
    Blindt R, Stellbrink K, de Taeye A, Müller R, Kiefer P, Yagmur E, Weber C, Kelm M, Hoffmann R.
    Thromb Haemost; 2007 Dec; 98(6):1329-34. PubMed ID: 18064332
    [Abstract] [Full Text] [Related]

  • 10. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.
    Gurbel PA, Bliden KP, Antonino MJ, Stephens G, Gretler DD, Jurek MM, Pakyz RE, Shuldiner AR, Conley PB, Tantry US.
    J Thromb Haemost; 2010 Jan; 8(1):43-53. PubMed ID: 19817997
    [Abstract] [Full Text] [Related]

  • 11. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [Abstract] [Full Text] [Related]

  • 12. Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.
    El Ghannudi S, Ohlmann P, Jesel L, Radulescu B, El Adraa E, Crimizade U, Wiesel ML, Gachet C, Morel O.
    Atherosclerosis; 2011 Aug; 217(2):465-72. PubMed ID: 21524751
    [Abstract] [Full Text] [Related]

  • 13. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
    [Abstract] [Full Text] [Related]

  • 14. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel.
    Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.
    J Thromb Haemost; 2010 Jan; 8(1):37-42. PubMed ID: 19818001
    [Abstract] [Full Text] [Related]

  • 15. High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention.
    Mangiacapra F, De Bruyne B, Muller O, Trana C, Ntalianis A, Bartunek J, Heyndrickx G, Di Sciascio G, Wijns W, Barbato E.
    JACC Cardiovasc Interv; 2010 Jan; 3(1):35-40. PubMed ID: 20129566
    [Abstract] [Full Text] [Related]

  • 16. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel.
    Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, ten Berg JM, Taubert D.
    J Thromb Haemost; 2010 Mar; 8(3):482-8. PubMed ID: 20040042
    [Abstract] [Full Text] [Related]

  • 17. Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis?
    Morel O, Bernhard N, Desprez D, Grunebaum L, Freyssinet JM, Toti F, Bareiss P.
    Thromb Haemost; 2008 Feb; 99(2):448-51. PubMed ID: 18278200
    [No Abstract] [Full Text] [Related]

  • 18. Impact of chronic kidney disease on platelet P2Y12 receptor signalling in patients with type 2 diabetes mellitus.
    Engwenyu LR, Franchi F, Rollini F, Cho JR, DeGroat C, Bhatti M, Alobaidi Z, Ferrante E, Jakubowski JA, Sugidachi A, Zenni M, Bass TA, Angiolillo DJ.
    Thromb Haemost; 2017 Jan 05; 117(1):201-203. PubMed ID: 27786340
    [No Abstract] [Full Text] [Related]

  • 19. Repeated high doses of clopidogrel in 2 cases of pharmacological resistance.
    Cayla G, Macia JC, Roubille F, Rabesendratana H, Piot C, Schved JF, Leclercq F.
    Circ J; 2008 Dec 05; 72(12):2098-100. PubMed ID: 18854615
    [Abstract] [Full Text] [Related]

  • 20. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay.
    Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B.
    J Thromb Haemost; 2010 Feb 05; 8(2):351-9. PubMed ID: 19943879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.